New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
March 5, 2015
11:58 EDTAETHealthCare USA wins MO HealthNet managed care contract
HealthCare USA of Missouri, an Aetna health plan that administers managed Medicaid services for MO HealthNet, has been selected by the Missouri Office of Administration, Division of Purchasing and Materials Management, to continue to provide access to health care for eligible Missourians. The new three-year contract is scheduled to take effect July 1.
07:56 EDTAET, MOH, HNT, CI, HUMLeerink more bullish on Managed Care after SCOTUS arguments
Subscribe for More Information
March 4, 2015
16:46 EDTWCGWellCare's Missouri Care Health Plan awarded Missouri Care Health contract
WellCare company Missouri Care Health Plan has selected the Missouri Office of Administration, Division of Purchasing and Materials Management, to continue serving Medicaid recipients participating in the MO HealthNet Managed Care program. The new contract begins July 1 and is for one year with two renewal options.
09:54 EDTAETAetna not reimbursing Exact Sciences for more than what law requires, says Maxim
Maxim said it views Exact Sciences' (EXAS) pact with Aetna (AET) for coverage for the Cologuard test for Medicare Advantage members as an incremental positive and the firm expects other insurers to follow Aetna's lead. However, the firm thinks the announcement indicates Exact Sciences has had talks with Aetna about reimbursement, but the insurer still isn't reimbursing for anything more than what the law requires of them. Maxim recommends shares be sold on the strength and reiterates its Sell rating on Exact Sciences.
08:31 EDTUNHInsperity forms broker alliance with UnitedHealth
Subscribe for More Information
08:17 EDTUNHUnitedHealth management to meet with Deutsche Bank
Meeting to be held in Kansas City, MO on March 4 hosted by Deutsche Bank.
07:57 EDTAETExact Sciences says Aetna Medicare Advantage to cover Cologuard
Exact Sciences (EXAS) announced that Aetna (AET) will cover Cologuard under its Medicare Advantage plan, reaching 967,000 members across the country. The three year agreement will go into effect on April 1. Cologuard is the first and only FDA approved noninvasive stool-based DNA screening test for colon cancer. The test will be available to Aetna’s Medicare Advantage members through their physician without a co-payment or co-insurance.
06:39 EDTCI, UNH, MOH, HUM, HNT, AET, CNC, WCGNo preparations under way for elimination of some subsidies, NY Times says
Subscribe for More Information
March 3, 2015
16:19 EDTCNCCentene announces successful reprocurement of managed care contract
Subscribe for More Information
08:37 EDTMDTFlex Pharma announces investment from Medtronic
Subscribe for More Information
08:02 EDTUNHUnitedHealth management to meet with Deutsche Bank
Subscribe for More Information
08:02 EDTBSXBoston Scientific acquisition positive, says Wells Fargo
Subscribe for More Information
07:56 EDTBSXBoston Scientific remains a top pick at JPMorgan
Subscribe for More Information
07:16 EDTHUM, HNTCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
March 2, 2015
16:26 EDTBSXOn The Fly: Closing Wrap
Subscribe for More Information
12:59 EDTMDTAppeals court ruling a positive for NuVasive, says Wells Fargo
Subscribe for More Information
12:54 EDTMDTNuVasive gets mixed appeals court ruling in patent fight with Medtronic
Subscribe for More Information
12:13 EDTSTJ, BSXOn The Fly: Midday Wrap
Subscribe for More Information
11:34 EDTSTJSt. Jude Medical shares up after ACC abstract, says Wells Fargo
Subscribe for More Information
08:55 EDTMDTEdwards Lifesciences Medtronic likely to get positive catalyst, says Wells Fargo
Subscribe for More Information
07:20 EDTHNTCowen to hold a conference
Subscribe for More Information
07:16 EDTBSXEndo to divest AMS men's and prostate health businesses to Boston Scientific
Endo International (ENDP) announced it has entered into a definitive agreement with Boston Scientific (BSX), under which Boston Scientific will acquire Endo's American Medical Systems' Men's and Prostate Health businesses for up to $1.65B, with $1.6B in cash payable at closing. Endo is also eligible to receive a potential milestone payment of $50M in cash conditioned on Boston Scientific achieving certain product revenue milestones in the Men's Health and Prostate Health businesses in 2016. In addition, Endo is currently evaluating strategic alternatives for the AMS Women's Health business. The transaction is expected to close in the third quarter of 2015, subject to customary conditions, including the expiration or termination of any applicable waiting periods under applicable competition laws. Endo will classify and report results of AMS as Discontinued Operations. FY15 Endo guidance will be provided on a continuing operations basis.
07:10 EDTBSXEndo to sell AMS urology portfolio to Boston Scientific for up to $1.65B
Boston Scientific (BSX) announced that it has entered into a definitive agreement with Endo International (ENDP) to acquire the American Medical Systems' urology portfolio, which includes the Men's Health and Prostate Health businesses, for $1.6B in up-front cash and a potential additional $50M milestone based on 2016 sales. The company expects to close the transaction in the third quarter of 2015, subject to customary closing conditions. Upon completion of the transaction, the AMS Men's Health and Prostate Health businesses will become part of Boston Scientific Urology and Women's Health. The acquisition encompasses the AMS product portfolio for treating urologic conditions, including benign prostatic hyperplasia, male stress urinary incontinence and erectile dysfunction. These technologies complement Boston Scientific's strong kidney stone, pelvic organ prolapse, female stress urinary incontinence and abnormal uterine bleeding treatment portfolios, and together, will provide customers with a comprehensive urology, urogynecology and gynecologic surgery portfolio. The AMS women's health business for treating pelvic organ prolapse and female stress urinary incontinence is not included in the transaction. The AMS Men's Health and Prostate Health businesses generated 2014 sales of approximately $400M and adjusted operating income of approximately $130M, excluding amortization and certain allocated expenses. GAAP operating income, including amortization and certain allocated expenses, was approximately $60M in 2014. The acquisition is expected to result in annual pre-tax synergies in excess of $50M by the end of 2018. On an adjusted basis, the transaction is expected to be breakeven to adjusted earnings per share in 2015, accretive by at least 3c in 2016, approximately 7c in 2017, and increasingly accretive thereafter. The transaction is expected to be less accretive, or dilutive, as the case may be, on a GAAP basis 2015 through 2017, due to amortization expense and transaction and integration costs. The acquisition is being structured as an asset purchase for tax purposes. Boston Scientific intends to finance the acquisition through a combination of existing and newly committed credit facilities.
07:08 EDTBSXEndo to sell AMS urology portfolio to Boston Scientific for up to $1.65B
Subscribe for More Information
07:08 EDTBSXBoston Scientific enters $1.65B agreement with Endo to acquire urology portfolio
Subscribe for More Information
February 27, 2015
16:38 EDTCICigna to reaffirm FY15 consolidated adjusted income from operations forecast
Subscribe for More Information
09:53 EDTCICigna management to meet with JPMorgan
Subscribe for More Information
09:02 EDTMDTMedtronic announces Irish High Court approval of share premium reduction
Subscribe for More Information
February 26, 2015
12:43 EDTSTJSt. Jude Medical management to meet with Piper Jaffray
Subscribe for More Information
February 24, 2015
14:31 EDTBSXBoston Scientific deal for Endo unit would be favorably received, says Needham
Subscribe for More Information
13:23 EDTAETAetna, Virtua Medical Group expand relationship
Subscribe for More Information
13:02 EDTMDTMedtronic confirms FDA approval of VenaSeal closure system
Subscribe for More Information
12:40 EDTBSXBoston Scientific may strike deal for Endo AMS unit within weeks, Reuters says
Boston Scientific (BSX) is reportedly close to buying Endo International's (ENDP) AMS medical device unit which could be valued at roughly $2B, reports Reuters, citing people familiar with the matter. The sources said the companies want to finalize a deal "within a matter of weeks" but cautioned that talks are continuing and could still fail. Reference Link
12:14 EDTBSXEndo near deal to sell AMS device unit to Boston Scientific, Reuters says
10:06 EDTCNCHigh option volume stocks
High option volume stocks: CHGG LBTYK SMH RCAP NGLS OTEX TERP CNC ALKS AMT
10:00 EDTSTJOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AMC Networks (AMCX) downgraded to Neutral from Outperform at Macquarie... American Airlines (AAL) downgraded to Market Perform at Cowen... Armstrong World (AWI) downgraded to Hold from Buy at KeyBanc... Basic Energy (BAS) downgraded to Outperform from Strong Buy at Raymond James... CSC (CSC) downgraded at Stifel... Chevron (CVX) downgraded to Perform from Outperform at Oppenheimer... Choice Hotels (CHH) downgraded to Underweight from Equal Weight at Barclays... Eni SpA (E) downgraded to Underperform from Hold at Jefferies... Fifth Street Asset (FSAM) downgraded to Neutral from Outperform at Credit Suisse... HSBC (HSBC) downgraded to Neutral from Buy at UBS... Home Loan Servicing (HLSS) downgraded to Neutral from Overweight at Piper Jaffray... Huntington Ingalls (HII) downgraded to Underperform from Neutral at Credit Suisse... International Paper (IP) downgraded to Hold from Buy at Deutsche Bank... Kayne Anderson (KED) downgraded at Stifel... Landstar System (LSTR) downgraded to Hold from Buy at Deutsche Bank... Multi-Color (LABL) downgraded to Neutral from Long-Term Buy at Hilliard Lyons... Newmont Mining (NEM) downgraded to Neutral from Overweight at HSBC... ONEOK Partners (OKS) downgraded to Underweight from Neutral at JPMorgan... ONEOK (OKE) downgraded to Underweight from Neutral at JPMorgan... Olympic Steel (ZEUS) downgraded to Underperform from Neutral at Credit Suisse... Polypore (PPO) downgraded to Market Perform from Outperform at William Blair... Rosetta Resources (ROSE) downgraded to Equal Weight from Overweight at Stephens... Salix (SLXP) downgraded to Neutral from Buy at UBS... Sprint (S) downgraded to Sell from Neutral at BTIG... St. Jude Medical (STJ) downgraded to Underperform from Outperform at Credit Suisse... Timmins Gold (TGD) downgraded on lack of near-term production catalysts at RBC Capital... Transocean Partners (RIGP) downgraded to Underweight from Equal Weight at Barclays... Vodafone (VOD) downgraded to Underperform from Neutral at BofA/Merrill... Williams Partners (WPZ) downgraded to Neutral from Buy at Citigroup... Williams (WMB) downgraded to Neutral from Buy at Citigroup... Worthington (WOR) downgraded to Neutral from Outperform at Credit Suisse... Zillow Group (Z) downgraded at Macquarie.
08:00 EDTCNCCentene subsidiary announces successful reprocurement of foster care contract
Subscribe for More Information
07:14 EDTSTJSt. Jude Medical downgraded to Underperform from Outperform at Credit Suisse
Credit Suisse downgraded St. Jude Medical two notches to Underperform based on expectations the Cardiac Rhythm Management segment and shares will under perform peers given competition from Medtronic's (MDT) Quadriplar ICD U.S. launch, Boston Scientific's (BSX) next-gen launch of its subcutaneious ICD, MRI-safe ICD competition in Japan, and the delay in the return of St. Jude's Nanostim to the European market. Price target is $74.
07:04 EDTCIUroplasty announces positive coverage decision for tibal nerve stimulation
Subscribe for More Information
February 23, 2015
19:40 EDTCI, AET, HNT, HUM, MOH, UNH, CNC, WCGLeerink healthcare services analyst holds an analyst/industry conference call
Subscribe for More Information
16:27 EDTHUM, UNH, WCGOn The Fly: Closing Wrap
Stocks on Wall Street began the session in negative territory and remained there for most of the session, with the Nasdaq the lone index to post a small gain. The Dow was weighed down by shares of Boeing (BA), which slid after the stock received a downgrade. There was little in the way of positive economic news, as the most notable report showed existing homes were lower than expected due to a shortage of inventory. The averages drifted for most of the session, as investors may be waiting on the sidelines ahead of tomorrow’s banking panel testimony by Fed Chair Janet Yellen. ECONOMIC EVENTS: In the U.S., the Chicago Fed national activity index rebounded to 0.13 in January, which was nearly in-line with expectations. Existing home sales dropped 4.9% to a 4.82M rate in January, which was much worse than the expected 1.8% drop to a 4.95M unit rate. In Europe, the Ifo Institute’s measure of German business confidence rose to 106.8 in February, which was up a tenth of a percentage point from the previous month but below the 107.7 consensus forecast. Also, the Bank of Israel became the latest central bank to cut rates this year, lowering its main interest rate to 0.1% from 0.25%. COMPANY NEWS: The shares of a number of health insurers rose after the Centers for Medicare and Medicaid Services, or CMS, issued preliminary 2016 Medicare Advantage rates. According to Credit Suisse, the rates were favorable for the insurers. Following the CMS announcement made late Friday, Humana (HUM) climbed $8.40, or 5.38%, to $164.52, UnitedHealth (UNH) rose $3.78, or 3.36%, to $116.40, and WellCare (WCG) gained $4.68, or 5.53%, to $89.30. MAJOR MOVERS: Among the notable gainers was PTC Therapeutics (PTCT), which jumped $9.77, or 17.7%, to $64.96 after Reuters said the company is working with financial advisers to explore a potential sale after receiving takeover interest from several companies including Shire (SHPG) and BioMarin (BMRN). Also higher was Valeant (VRX), which rose $25.49, or 14.71%, to $198.75 after the company agreed to buy Salix (SLXP) for $158 per share and also reported better-than-forecast earnings. Salix shares, however, fell $2.09, or 1.32%, to $155.76, as a report Friday from CNBC's David Faber telegraphed the deal and suggested Valeant could value Salix around $160 per share. Among the noteworthy losers was Spectrum Pharmaceuticals (SPPI), which dropped $1.18, or 15.82%, to $6.28 after a judge ruled that a drug which could compete with the company's Fusilev treatment does not infringe on the company's intellectual property. Also lower were shares of Boeing, which fell $3.57, or 2.26%, to $154.74 after the stock was downgraded to Sell from Neutral at Goldman Sachs. INDEXES: The Dow fell 23.60, or 0.13%, to 18,116.84, the Nasdaq gained 5.01, or 0.1%, to 4,960.97, and the S&P 500 slipped 0.64, or 0.03%, to 2,109.66.
12:21 EDTAET, MOH, WCG, CNC, CI, HS, HNT, UNH, HUMOn The Fly: Midday Wrap
Subscribe for More Information
11:10 EDTWCG, MOH, AGP, AET, CI, CNC, HNT, HS, UNH, HUMHealth insurers rise after CMS releases preliminary Medicare Advantage rates
The shares of a number of health insurers are rising after the Centers for Medicare and Medicaid Services, or CMS, issued preliminary 2016 Medicare Advantage rates. According to Credit Suisse, the rates were favorable for health insurers. WHAT'S NEW: On Friday after the market closed, CMS issued a proposal for 2016 Medicare Advantage rates. The rates are preliminary and could change when CMS announces the final 2016 rates on April 6 of this year, the agency noted. In a note to investors earlier today, Credit Suisse analyst Ralph Giacobbe estimated that, under CMS' initial proposal, insurers would see rate changes of between -1% and +1%, depending on the risk that each insurer faces. The preliminary rates were "favorable" for insurers, since the rates were "in-line if not slightly better" than investors had expected, the firm stated. Moreover, CMS decided not to restrict at-home health risk assessments, as had been feared, and agreed to reduce the weighting of certain risk factors that had hurt previously certain plans with a higher proportion of low-income beneficiaries, acceding to a request by insurers. Insurers with the highest exposure to Medicare Advantage include Humana (HUM), UnitedHealth (UNH), and WellCare (WCG), the analyst stated. WHAT'S NOTABLE: After analyzing CMS' proposal, health insurer Aetna (AET) estimated that the proposal would cause government funding for its Medicare Advantage business to decline by about 1% in 2016. Aetna added that it is continuing to evaluate the changes outlined in the Advance Notice and their impact on the company and its Medicare Advantage members. OTHERS TO WATCH: Other publicly traded health insurance companies include Anthem (ANTM), AMERIGROUP (AGP), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), and Molina Healthcare (MOH). PRICE ACTION: In mid-morning trading, Humana climbed 5.3% to $164.43, UnitedHealth rose 2.6% to $115.56, WellCare gained 6.3% to $90, Aetna advanced 2% to $99.91, and Centene added 3.4% to $61.93.
09:33 EDTHUMHumana 'evaluating all operational avenues' after CMS notice
Subscribe for More Information
09:03 EDTAETAetna sees preliminary CMS rates to lower funding for MA business 1% in 2016
Subscribe for More Information
08:40 EDTMDTMedtronic acquires Advanced Uro-Solutions, terms not disclosed
Medtronic announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed.
08:05 EDTCNC, CI, WCG, AGP, AET, MOH, HNT, HUM, UNH, HSCMS releases preliminary Medicare Advantage rates for 2016
Subscribe for More Information
February 20, 2015
14:43 EDTSTJSt. Jude Medical raises quarterly dividend 7%
Subscribe for More Information
12:19 EDTMDTFDA approves closure system to permanently treat varicose veins
Subscribe for More Information
08:51 EDTMOHMolina Healthcare estimates raised above Street at Sterne Agee
Sterne Agee raised its 2015 EPS estimate for Molina to $3 from $2.13 and increased its 2016 EPS estimate for the company to $4 from $2.95. The firm thinks the company's medical cost results will be better than its current guidance.
08:41 EDTAET, CI, UNHInsurers should be bought on weakness related to MA rates, says BMO Capital
Subscribe for More Information
07:08 EDTBSXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
16:15 EDTMDTMedtronic SANTE trial data show sustained safety, improvements in QOLIE-31
Subscribe for More Information
10:42 EDTHUMHumana discloses DoJ Civil Division request for information
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use